Technical note: not for editorial use
MAINZ, Germany, January 23, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) has completed construction of the Company’s first plasmid DNA production facility at its Marburg site. Plasmid DNA is a key starting material for the production of mRNA-based vaccines and therapies. With this new facility, BioNTech is strengthening the Company's manufacturing capabilities for mRNA-based products. German Chancellor Olaf Scholz will visit the new manufacturing facility in Marburg on February 2, 2023. BioNTech invites media representatives to participate in the event.
As part of the visit, an open photo opportunity will take place for the accredited press to accompany the arrival as well as the press statements at the end of the event with German Chancellor Olaf Scholz as well as Ugur Sahin, co-founder and CEO of BioNTech, and Özlem Türeci, co-founder and Chief Medical Officer of BioNTech. Due to space restrictions, an additional photo opportunity in the new manufacturing area can unfortunately only be offered to those responsible for photos and video.
We kindly ask interested media representatives to accredit themselves by Monday, January 30, 2023, 00:00 am CET by sending the following information via e-mail to media@biontech.de with the subject “Visit of Chancellor Scholz to BioNTech”:
- Last name, first name
- Date of birth
- Place of birth
- Medium
- Function
More detailed information will be provided in a separate press briefing after accreditation. Please note that a subsequent accreditation on site is not possible.
About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific immune checkpoint modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer. For more information, please visit www.BioNTech.com.
CONTACTS
Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de
Investor Relations
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
Investors@biontech.de
